$135m private health push in West Bengal
This article was originally published in Clinica
The Indian joint venture SPS Synergy Foundation - made up of steel and power firm SPS Group and the Synergy Group, which works in the field of scientific agriculture and renewable energy besides running educational institutions - is to invest Rs6bn ($135m) in a health complex.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.